Antisense Pharma Receives FDA Orphan Drug Designation for Trabedersen to Treat Malignant Melanoma
TGF-β2 inhibitor has gained market exclusivity in the USA for a third aggressive cancer indication
25-Jul-2012
- Germany
Previously, trabedersen has received Orphan Drug designation by the European EMA and the US FDA in high-grade glioma (malignant brain tumor) in 2002 and in advanced pancreatic cancer in 2009.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.